Ideas – Page 26

October 12, 2019

Published by admin_auro at October 12, 2019

Categories

Cancer
Ideas

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib (Trade name: Vizimpro, and PF-00299804) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1, p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers progression, and prolongs survival, via up-regulation of its target gene, 13/October/2019, 12.55 am

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, […]

October 4, 2019

Published by admin_auro at October 4, 2019

Categories

Cancer
Ideas

Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancer and in other advanced metastatic cancers: A pharmaceutical mixture encompassing Palbociclib, Letrozole and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PDCD4, ACAT1, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls advanced breast cancer progression, via up-regulation of its target gene, 5/October/2019, 1.00 am

Introduction: What they say A study from Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los […]

October 1, 2019

Published by admin_auro at October 1, 2019

Categories

Cardiovascular Polypill-LAAH attenuates pathogenesis-associated with Myocardial infarction and protects against myocardial dysfunction: A four-component Polypill-LAAH consisting of Losartan(25 mg), Amlodipine (2.5 mg), Atorvastatin (10 mg), and Hydrochlorothiazide (12·5 mg)decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target genes, 1/October/2019, 12.04 pm

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and […]

September 26, 2019

Published by admin_auro at September 26, 2019

Categories

Molecular mechanistic insight into how Dapagliflozin (DAPA) protects against and promotes functional recovery after Myocardial Infarction: Dapagliflozin (DAPA) (trade name: Forxiga, Farxiga, others), a medication used to treat type II diabetes, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 26/September/2019, 3.58 pm

What they say: A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of of […]